一项新的研究显示Actos, 一种普遍应用的控制血糖药, 可防止糖尿病患者的心脏病发作, 中风和死亡。 今天在第41届欧洲糖尿病研究协会的会议上, 一项研究展示了里程碑式的数据。历经3年来自5,200例糖尿病患者的研究显示, ACTOS.(pioglitazone HCl)极大地 (16%)减少了高危II型糖尿病患者的心脏病发作, 中风和死亡的综合风险。在前瞻性研究中, 这是首次显示口服糖尿病药有此益处。

ACTOS, an insulin sensitizer belonging to the thiazolidinedione (TZD) class of oral anti-diabetic medications, directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ACTOS is taken once daily as an adjunct to diet and exercise, and is approved for use in type 2 diabetes as monotherapy to lower blood glucose and in combination therapy with insulin, sulfonylureas or metformin

See Story from Forbes